pharmaphorum
OCTOBER 27, 2020
The company opted to test merimepodib in the combination trial first as that had the greatest potential to make a difference to patients, but the safety issue means that it has decided to halt development of the drug altogether. The post BioSig abandons COVID-19 drug trial on safety concerns appeared first on.
Drug Discovery World
MAY 21, 2024
Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. These targets, along with many others, are universally deemed as ‘difficult-to-drug’ targets.
Pharmaceutical Technology
SEPTEMBER 20, 2022
Unlike commercial pharmaceutical packaging, the primary consideration in clinical trial packaging is protecting the product quality and reliability for research. Finding the best clinical trial packaging services providers.
Expert insights. Personalized for you.
97 
Let's personalize your content